IL6 and myeloid sarcoma: Studies have revealed, similarly to EGCG, its capacity to target key inflammatory cytokines implicated in MS pathogenesis, including TNF-α, IL-1β, IL-6, IL-17, and IFN-γ, effectively dampening the inflammatory cascade [226,237].